CN100349867C - 制备r,r(或s,s)构型的格隆铵-立体异构体的方法 - Google Patents
制备r,r(或s,s)构型的格隆铵-立体异构体的方法 Download PDFInfo
- Publication number
- CN100349867C CN100349867C CNB2003801098187A CN200380109818A CN100349867C CN 100349867 C CN100349867 C CN 100349867C CN B2003801098187 A CNB2003801098187 A CN B2003801098187A CN 200380109818 A CN200380109818 A CN 200380109818A CN 100349867 C CN100349867 C CN 100349867C
- Authority
- CN
- China
- Prior art keywords
- formula
- solvent
- isomers
- diastereomer
- diastereomer mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- ANGKOCUUWGHLCE-HKUYNNGSSA-N [(3s)-1,1-dimethylpyrrolidin-1-ium-3-yl] (2r)-2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical class C1[N+](C)(C)CC[C@@H]1OC(=O)[C@](O)(C=1C=CC=CC=1)C1CCCC1 ANGKOCUUWGHLCE-HKUYNNGSSA-N 0.000 title claims abstract description 12
- 238000004519 manufacturing process Methods 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 54
- 125000001544 thienyl group Chemical group 0.000 claims abstract description 16
- 239000000203 mixture Substances 0.000 claims description 66
- 239000002904 solvent Substances 0.000 claims description 47
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 37
- 238000005956 quaternization reaction Methods 0.000 claims description 33
- 238000001953 recrystallisation Methods 0.000 claims description 31
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 229960002462 glycopyrronium bromide Drugs 0.000 claims description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 238000002425 crystallisation Methods 0.000 claims description 17
- 239000002244 precipitate Substances 0.000 claims description 17
- 230000008025 crystallization Effects 0.000 claims description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical class CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
- 150000003839 salts Chemical group 0.000 claims description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 9
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 6
- 238000009835 boiling Methods 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 6
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims description 6
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 2
- ANGKOCUUWGHLCE-UHFFFAOYSA-N 2-cyclopentyl-2-hydroxy-2-phenylacetic acid (1,1-dimethyl-3-pyrrolidin-1-iumyl) ester Chemical compound C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 ANGKOCUUWGHLCE-UHFFFAOYSA-N 0.000 claims 3
- 239000012141 concentrate Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 description 20
- 238000005809 transesterification reaction Methods 0.000 description 17
- 239000002253 acid Substances 0.000 description 10
- -1 salt compound Chemical class 0.000 description 10
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- 239000012043 crude product Substances 0.000 description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 238000004611 spectroscopical analysis Methods 0.000 description 7
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 6
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 5
- 150000001414 amino alcohols Chemical class 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- FLVFPAIGVBQGET-YFKPBYRVSA-N (3s)-1-methylpyrrolidin-3-ol Chemical compound CN1CC[C@H](O)C1 FLVFPAIGVBQGET-YFKPBYRVSA-N 0.000 description 4
- FLVFPAIGVBQGET-UHFFFAOYSA-N 1-methylpyrrolidin-3-ol Chemical compound CN1CCC(O)C1 FLVFPAIGVBQGET-UHFFFAOYSA-N 0.000 description 4
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 229940015042 glycopyrrolate Drugs 0.000 description 4
- KXKVLQRXCPHEJC-UHFFFAOYSA-N methyl acetate Chemical compound COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 239000011877 solvent mixture Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 229940102396 methyl bromide Drugs 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- FLVFPAIGVBQGET-RXMQYKEDSA-N (3r)-1-methylpyrrolidin-3-ol Chemical compound CN1CC[C@@H](O)C1 FLVFPAIGVBQGET-RXMQYKEDSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 2
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- FGMUSNHTKNGVQD-UHFFFAOYSA-N methyl 2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C=1C=CC=CC=1C(O)(C(=O)OC)C1CCCC1 FGMUSNHTKNGVQD-UHFFFAOYSA-N 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 238000012916 structural analysis Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- OVGMKPGXRHJNKJ-UHFFFAOYSA-N (1-methylpyrrolidin-3-yl) 2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C1N(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 OVGMKPGXRHJNKJ-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 206010004663 Biliary colic Diseases 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 208000021891 Micturition disease Diseases 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 206010038419 Renal colic Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- FGMUSNHTKNGVQD-AWEZNQCLSA-N methyl (2r)-2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C1([C@](O)(C(=O)OC)C=2C=CC=CC=2)CCCC1 FGMUSNHTKNGVQD-AWEZNQCLSA-N 0.000 description 1
- FGMUSNHTKNGVQD-CQSZACIVSA-N methyl (2s)-2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C1([C@@](O)(C(=O)OC)C=2C=CC=CC=2)CCCC1 FGMUSNHTKNGVQD-CQSZACIVSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims (12)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ATA1896/2002 | 2002-12-18 | ||
AT0189602A AT412088B (de) | 2002-12-18 | 2002-12-18 | Verfahren zur herstellung der r,r oder s,s konfigurierten glycopyrronium-isomere |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1751022A CN1751022A (zh) | 2006-03-22 |
CN100349867C true CN100349867C (zh) | 2007-11-21 |
Family
ID=31192804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2003801098187A Expired - Fee Related CN100349867C (zh) | 2002-12-18 | 2003-12-18 | 制备r,r(或s,s)构型的格隆铵-立体异构体的方法 |
Country Status (15)
Country | Link |
---|---|
US (1) | US7569598B2 (zh) |
EP (1) | EP1572641B1 (zh) |
JP (1) | JP2007524565A (zh) |
CN (1) | CN100349867C (zh) |
AT (2) | AT412088B (zh) |
AU (1) | AU2003290075B2 (zh) |
CA (1) | CA2510280C (zh) |
DK (1) | DK1572641T3 (zh) |
ES (1) | ES2383799T3 (zh) |
NO (1) | NO330851B1 (zh) |
NZ (1) | NZ541098A (zh) |
PL (1) | PL214802B1 (zh) |
PT (1) | PT1572641E (zh) |
RU (1) | RU2337096C2 (zh) |
WO (1) | WO2004054971A1 (zh) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0504463D0 (en) * | 2005-03-03 | 2005-04-13 | Arakis Ltd | Method of crystallisation and purification |
US20120022127A1 (en) | 2009-04-09 | 2012-01-26 | Thomas Allmendinger | Process for preparing pyrrolidinium salts |
ES2528957T3 (es) * | 2010-06-14 | 2015-02-13 | Chiesi Farmaceutici S.P.A. | Forma cristalina del cloruro de glicopirronio |
CN103159659A (zh) * | 2011-12-19 | 2013-06-19 | 沈阳药科大学 | 一种毒蕈碱受体拮抗剂格隆溴铵的制备方法 |
SI2607351T1 (sl) * | 2011-12-22 | 2017-07-31 | Cerbios-Pharma S.A. | Neprekinjen proces za alkiliranje cikličnih terciarnih aminov |
CN102627595A (zh) * | 2012-03-09 | 2012-08-08 | 徐奎 | 一种制备格隆溴铵的方法 |
KR102232806B1 (ko) | 2013-02-28 | 2021-03-29 | 더미라, 인코포레이티드 | 글리코피롤레이트 염 |
US9006462B2 (en) | 2013-02-28 | 2015-04-14 | Dermira, Inc. | Glycopyrrolate salts |
US8558008B2 (en) | 2013-02-28 | 2013-10-15 | Dermira, Inc. | Crystalline glycopyrrolate tosylate |
CN104586841A (zh) * | 2013-10-30 | 2015-05-06 | 中国药科大学 | (3r,2’r)-格隆溴铵作为m3毒蕈碱性受体拮抗剂在制药中的用途 |
CN107304178B (zh) * | 2016-04-21 | 2020-03-27 | 辽宁药联制药有限公司 | 一种毒蕈碱受体拮抗剂格隆溴铵手性对映体的制备方法 |
CN107345945B (zh) * | 2016-05-05 | 2019-12-17 | 辽宁药联制药有限公司 | 一种拆分格隆溴铵对映体及杂质检查的高效液相色谱方法 |
CN113234003B (zh) * | 2021-04-23 | 2024-02-02 | 广东嘉博制药有限公司 | 一种格隆溴铵及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1237159A (zh) * | 1996-11-11 | 1999-12-01 | 克里斯琴R·诺埃 | 对映导构纯的碱性芳基-环烷基-羟基羧酸酯,其制备方法及其在药品中的应用 |
-
2002
- 2002-12-18 AT AT0189602A patent/AT412088B/de not_active IP Right Cessation
-
2003
- 2003-12-18 RU RU2005122497/04A patent/RU2337096C2/ru active
- 2003-12-18 WO PCT/EP2003/014432 patent/WO2004054971A1/de active Application Filing
- 2003-12-18 AU AU2003290075A patent/AU2003290075B2/en not_active Ceased
- 2003-12-18 PL PL377441A patent/PL214802B1/pl unknown
- 2003-12-18 CN CNB2003801098187A patent/CN100349867C/zh not_active Expired - Fee Related
- 2003-12-18 AT AT03782435T patent/ATE548348T1/de active
- 2003-12-18 CA CA2510280A patent/CA2510280C/en not_active Expired - Fee Related
- 2003-12-18 US US10/540,187 patent/US7569598B2/en active Active
- 2003-12-18 DK DK03782435.6T patent/DK1572641T3/da active
- 2003-12-18 JP JP2004560470A patent/JP2007524565A/ja active Pending
- 2003-12-18 ES ES03782435T patent/ES2383799T3/es not_active Expired - Lifetime
- 2003-12-18 PT PT03782435T patent/PT1572641E/pt unknown
- 2003-12-18 NZ NZ541098A patent/NZ541098A/en not_active IP Right Cessation
- 2003-12-18 EP EP03782435A patent/EP1572641B1/de not_active Expired - Lifetime
-
2005
- 2005-07-15 NO NO20053473A patent/NO330851B1/no not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1237159A (zh) * | 1996-11-11 | 1999-12-01 | 克里斯琴R·诺埃 | 对映导构纯的碱性芳基-环烷基-羟基羧酸酯,其制备方法及其在药品中的应用 |
Non-Patent Citations (1)
Title |
---|
Use of cyclodextrins as chiral selector for the chiral separationof anticholonergic drugs such as anisodamine andglycopyrronium in capillary zone electrophoresis. wang zhi et.al.J. high resolut. Chromatogr,Vol.19 No.12. 1996 * |
Also Published As
Publication number | Publication date |
---|---|
AU2003290075A1 (en) | 2004-07-09 |
DK1572641T3 (da) | 2012-07-02 |
PL214802B1 (pl) | 2013-09-30 |
CA2510280C (en) | 2011-09-27 |
NO20053473L (no) | 2005-09-19 |
CN1751022A (zh) | 2006-03-22 |
AU2003290075B2 (en) | 2009-01-29 |
NZ541098A (en) | 2008-08-29 |
ATE548348T1 (de) | 2012-03-15 |
NO330851B1 (no) | 2011-08-01 |
CA2510280A1 (en) | 2004-07-01 |
RU2337096C2 (ru) | 2008-10-27 |
WO2004054971A1 (de) | 2004-07-01 |
US7569598B2 (en) | 2009-08-04 |
EP1572641B1 (de) | 2012-03-07 |
NO20053473D0 (no) | 2005-07-15 |
RU2005122497A (ru) | 2006-01-20 |
US20060167275A1 (en) | 2006-07-27 |
PL377441A1 (pl) | 2006-02-06 |
EP1572641A1 (de) | 2005-09-14 |
PT1572641E (pt) | 2012-06-15 |
ATA18962002A (de) | 2004-02-15 |
JP2007524565A (ja) | 2007-08-30 |
ES2383799T3 (es) | 2012-06-26 |
AT412088B (de) | 2004-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100349867C (zh) | 制备r,r(或s,s)构型的格隆铵-立体异构体的方法 | |
CN1218940C (zh) | 氧化氮合酶抑制剂 | |
CN1102829A (zh) | 紫杉酚、紫杉酚类似物及其中间体的合成及它的组合物 | |
CN1446812A (zh) | 光学活性的哌啶化合物的酸加成盐和其制备方法 | |
CN101076515A (zh) | 制备3-吡咯烷-2-基-丙酸衍生物的新方法 | |
CN1039910C (zh) | 雪花胺衍生物、其制备方法及其作为药物的用途 | |
CN1186315C (zh) | o-茴香酰胺衍生物 | |
CN1280258C (zh) | 4,5-二氨基莽草酸衍生物的制备方法 | |
CN1048014C (zh) | 取代的吡咯类化合物及其制法、药物组合物和用途 | |
CN1025030C (zh) | 吡喃并苯并噁二唑的旋光拆分方法 | |
CN1100098A (zh) | 2-氨基-4-喹啉基-二氢吡啶类化合物及其制备和应用 | |
CN1168713C (zh) | 制备鼻病毒蛋白酶抑制剂的合成路线以及关键的中间体 | |
CN1030611C (zh) | 形式ii地红霉素的制备方法 | |
CN1083425C (zh) | 由环氧化物制备顺式-1-氨基-2-链烷醇的区域专一性方法 | |
CN1679535A (zh) | 含有普伐他汀钠的组合物 | |
CN1869033A (zh) | R-硫辛酸的氨基丁三醇盐的新的变性体及其制备方法 | |
CN101056876A (zh) | 取代的8-氮杂双环[3.2.1]辛-3-醇的制备方法 | |
CN1305486A (zh) | 从α-D-木糖衍生的新化合物,制备方法和治疗用途 | |
CN1735588A (zh) | 由d-和l-天冬氨酸合成(r)和(s)-氨基肉碱及其衍生物 | |
CN1090635C (zh) | 头孢菌素晶体及其制备方法 | |
CN1310940C (zh) | 三萜衍生物的制备方法 | |
CN1216054C (zh) | 1,4-二氢吡啶-3,5-二羧酸衍生物及其制备方法 | |
CN1308312C (zh) | 石杉碱乙双分子和双功能团衍生物、制备方法及它的用途 | |
CN1946708A (zh) | 苯并氧硫烷的合成方法和中间体 | |
CN1322200A (zh) | 对映体选择性合成 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: MEHTA MEDICINE LIMITED PARTNERSHIP Free format text: FORMER OWNER: PHARMACON FORSCHUNG UND BERATU Effective date: 20080731 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20080731 Address after: German Homburg Patentee after: MEDA Pharma GmbH & Co.KG Address before: Austria scharding Patentee before: PHARMACON-FORSCHUNG UND BERATUNG GmbH |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20071121 Termination date: 20211218 |
|
CF01 | Termination of patent right due to non-payment of annual fee |